Cargando…

Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting

OBJECTIVES: There is a limited amount of literature examining the burden and cost of illness of acute coronary syndrome (ACS) in the managed care population. The goal of this study was to estimate the total cost of health care utilization (health plan plus patient) in the 12-month period following n...

Descripción completa

Detalles Bibliográficos
Autores principales: Etemad, Lida R., McCollam, Patrick L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437354/
https://www.ncbi.nlm.nih.gov/pubmed/15871640
http://dx.doi.org/10.18553/jmcp.2005.11.4.300
_version_ 1785092503516479488
author Etemad, Lida R.
McCollam, Patrick L.
author_facet Etemad, Lida R.
McCollam, Patrick L.
author_sort Etemad, Lida R.
collection PubMed
description OBJECTIVES: There is a limited amount of literature examining the burden and cost of illness of acute coronary syndrome (ACS) in the managed care population. The goal of this study was to estimate the total cost of health care utilization (health plan plus patient) in the 12-month period following newly onset ACS. The demographic and health characteristics of these patients are compared with the similar data from 2 large clinical trials: CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) and PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy Thrombolysis in Myocardial Infarction 22). METHODS: A retrospective claims analysis was conducted for the 2-year period from July 1, 1999, through June 30, 2001. ACS was defined as an emergency room visit or hospitalization with a primary International Classification of Diseases, 9th Edition/Revision (ICD-9) diagnosis of 410.xx (acute myocardial infarction) or 411.1x (intermediate coronary syndrome). Patients were required to be free of any ACS claim in the previous 6 months. Patients without 6 months of prior continuous enrollment or those patients younger than 18 years were excluded. Patients were followed up to 12 months to identify total medical and pharmacy costs, revascularization procedures, and medication use. RESULTS: A total of 13,731 patients met the inclusion criteria, yielding 133,814 months of follow-up (mean: 9.75 months per patient) and representing approximately 0.4% of the managed care members in the database during the study period. The mean age was 54 years and 68% were male. The total direct cost incurred by the health plan and patients was $309 million ($2,312 per patient month of follow-up); 72% of total costs were attributable to hospitalizations. The majority of costs were medical ($286 million, 93%), and $23 million (7%) were pharmacy costs. Fifty-one percent of patients had a revascularization procedure, which was typically performed during the index hospitalization (median time to revascularization was 0 days). Coronary artery stent implantation was the most common revascularization procedure (68%). During follow-up, 490 patients (3.6%) had a detectable death, 58% of patients received a beta-blocker, 60% received one or more cholesterol-lowering medications, and 36% of patients received clopidogrel therapy. Aspirin therapy was not measured. CONCLUSIONS: These managed-care patients with newly onset ACS incurred substantial costs in the 12 months following initial presentation. Revascularization was a common therapeutic intervention for these patients. There appear to be opportunities to improve medication therapy after an acute ACS event. There were some demographic and health characteristics that were different in these commercially insured patients from those in 2 large clinical trials.
format Online
Article
Text
id pubmed-10437354
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104373542023-08-21 Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting Etemad, Lida R. McCollam, Patrick L. J Manag Care Pharm Research OBJECTIVES: There is a limited amount of literature examining the burden and cost of illness of acute coronary syndrome (ACS) in the managed care population. The goal of this study was to estimate the total cost of health care utilization (health plan plus patient) in the 12-month period following newly onset ACS. The demographic and health characteristics of these patients are compared with the similar data from 2 large clinical trials: CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) and PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy Thrombolysis in Myocardial Infarction 22). METHODS: A retrospective claims analysis was conducted for the 2-year period from July 1, 1999, through June 30, 2001. ACS was defined as an emergency room visit or hospitalization with a primary International Classification of Diseases, 9th Edition/Revision (ICD-9) diagnosis of 410.xx (acute myocardial infarction) or 411.1x (intermediate coronary syndrome). Patients were required to be free of any ACS claim in the previous 6 months. Patients without 6 months of prior continuous enrollment or those patients younger than 18 years were excluded. Patients were followed up to 12 months to identify total medical and pharmacy costs, revascularization procedures, and medication use. RESULTS: A total of 13,731 patients met the inclusion criteria, yielding 133,814 months of follow-up (mean: 9.75 months per patient) and representing approximately 0.4% of the managed care members in the database during the study period. The mean age was 54 years and 68% were male. The total direct cost incurred by the health plan and patients was $309 million ($2,312 per patient month of follow-up); 72% of total costs were attributable to hospitalizations. The majority of costs were medical ($286 million, 93%), and $23 million (7%) were pharmacy costs. Fifty-one percent of patients had a revascularization procedure, which was typically performed during the index hospitalization (median time to revascularization was 0 days). Coronary artery stent implantation was the most common revascularization procedure (68%). During follow-up, 490 patients (3.6%) had a detectable death, 58% of patients received a beta-blocker, 60% received one or more cholesterol-lowering medications, and 36% of patients received clopidogrel therapy. Aspirin therapy was not measured. CONCLUSIONS: These managed-care patients with newly onset ACS incurred substantial costs in the 12 months following initial presentation. Revascularization was a common therapeutic intervention for these patients. There appear to be opportunities to improve medication therapy after an acute ACS event. There were some demographic and health characteristics that were different in these commercially insured patients from those in 2 large clinical trials. Academy of Managed Care Pharmacy 2005-05 /pmc/articles/PMC10437354/ /pubmed/15871640 http://dx.doi.org/10.18553/jmcp.2005.11.4.300 Text en Copyright © 2005, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research
Etemad, Lida R.
McCollam, Patrick L.
Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting
title Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting
title_full Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting
title_fullStr Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting
title_full_unstemmed Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting
title_short Total First-Year Costs of Acute Coronary Syndrome in a Managed Care Setting
title_sort total first-year costs of acute coronary syndrome in a managed care setting
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437354/
https://www.ncbi.nlm.nih.gov/pubmed/15871640
http://dx.doi.org/10.18553/jmcp.2005.11.4.300
work_keys_str_mv AT etemadlidar totalfirstyearcostsofacutecoronarysyndromeinamanagedcaresetting
AT mccollampatrickl totalfirstyearcostsofacutecoronarysyndromeinamanagedcaresetting